Shenzhen, China – Oct 27 2022
XtalPi Inc., a leading AI-powered pharmaceutical technology company, announced a strategic research collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to accelerate the discovery of small molecule therapeutics. Facilitated by Johnson & Johnson Innovation LLC, this partnership aims to deliver validated chemical matter with optimized binding affinities and desirable property profiles for a target nominated by Janssen.
AI and Automation to Enhance Drug Discovery
Under the collaboration, XtalPi will leverage its end-to-end Inclusive Digital Drug Discovery & Development (ID4) platform to accelerate the drug discovery process. The ID4 platform integrates AI-powered predictive modeling, cloud-based computations, and state-of-the-art wet lab capabilities to shorten the Design-Make-Test-Analyze (DMTA) cycle and enhance the efficiency of early-stage drug discovery.
Key Capabilities of XtalPi’s ID4 Platform:
- AI-driven molecular design – Predicting and optimizing small molecule interactions with high accuracy.
- Automated synthesis and testing – Combining computational chemistry with high-throughput robotic experimentation.
- Iterative optimization cycles – Refining candidates through continuous AI-model enhancements.
“We are excited to put our ID4 platform to the test in collaboration with Janssen,” said Dr. Jian Ma, CEO of XtalPi. “By integrating AI, automation, and domain expertise, we aim to accelerate the identification of promising drug candidates and help bring innovative treatments to patients faster.”
Scaling AI’s Role in Pharmaceutical R&D
XtalPi has built a strong reputation for its success in solid-state polymorphism prediction and has expanded its capabilities to address broader challenges in drug discovery. With significant investments in automation, medicinal chemistry, synthetic chemistry, and AI-driven predictive modeling, XtalPi now provides a comprehensive solution supporting early-stage drug development.
This partnership underscores the increasing adoption of AI-driven drug discovery by global pharmaceutical leaders. By integrating AI with experimental validation, XtalPi and Janssen aim to redefine traditional drug discovery processes, making them more efficient, scalable, and data-driven.
About XtalPi
XtalPi is a leading AI-driven pharmaceutical technology company that leverages AI, quantum mechanics, and robotic automation to accelerate drug discovery and development. With a global presence and collaborations with over 200 pharmaceutical and biotech companies, XtalPi is advancing the next generation of therapeutics. More about news
By
